An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Harbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...

Dedicated datasets highlight how social determinants of health can be used to improve overall standards of care.

Discover why leaders in the pharmaceutical industry are investing in future-ready, smart digital strategies for process ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.